Author: NSV
iCAD – New research supporting ProFound AI presented at European congress of radiology online meeting
iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced new research supporting ProFound AI® was presented at the European Congress of Radiology (ECR) 2021 Online meeting, taking place March 3-10, 2021. During the congress, the Company also showcased the full suite
Read More
Isorg obtains FBI certification for security market’s first organic photodiode-based module for fingerprint scanners
Isorg, a pioneer in organic photodetectors (OPDs) and large-area image sensors, today announces its Fingerprint Acquisition Profile (FAP) 10 module has received FBI certification, the first in this category of organic photodiode (OPD) based optical sensors. The FAP 10 biometrics module is now approved for use in security applications, in
Read MoreiCAD announces closing of $25.0 million public offering of common stock and full exercise of underwriters’ option to purchase additional shares
iCAD, Inc. (the “Company”, NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced the closing on March 5, 2021 of its previously announced underwritten public offering of 1,393,738 shares of common stock at a public offering price of $18.00 per share, which included
Read More
DataCore Software acquires Caringo, Inc.
DataCore Software, the authority on software-defined storage, today announced that it has acquired Caringo, Inc. The combined entity will enable DataCore to offer complete, best-of-breed software-defined storage solutions for block, file, and object—from a single vendor. The acquisition will also add talent and expertise to the DataCore team, as well
Read More
New Science Ventures announces merger of its portfolio company Achronix with ACE Convergence
New Science Ventures LLC (“NSV”), a leading venture capital firm focused on building companies that leverage breakthrough science to create extraordinary value, today announces the merger of its portfolio company, Achronix Semiconductor Corporation (“Achronix”), with ACE Convergence Acquisition Corp. NSV is a founding investor in Achronix. Highlights: Achronix is the
Read More
NorthSea Therapeutics reports Positive Phase 2b interim results for icosabutate in NASH patients
NorthSea Therapeutics B.V., (‘NST’) a Dutch biotech company developing novel and innovative therapies for NASH (Non-alcoholic Steatohepatitis) and other metabolic, inflammatory, and fibrotic diseases based on its SEFA (Structurally Engineered Fatty Acid) technology, today announced a positive interim readout of its ICONA Phase 2b study. The ICONA study (ICOsabutate in
Read More
Resolve Therapeutics announces clinically meaningful improvement in patients with Systemic lupus erythematosus in Phase 2a clinical trial
Resolve Therapeutics, pioneering first-in-class, targeted, safe therapies for underserved autoimmune diseases, today announced results from its Phase 2a study of RSLV-132 in patients with Systemic lupus erythematosus (SLE). Sixty-six patients diagnosed with SLE and a CLASI score of ≥ 10 at screening were enrolled into the study at 19 clinical
Read MoreResolve Therapeutics publishes positive Sjogren’s syndrome clinical trial results
Resolve Therapeutics, pioneering first-in-class, targeted, safe therapies for underserved autoimmune diseases, today announced publication of results from its Phase 2 study of RSLV-132 for the treatment of primary Sjogren’s syndrome (pSS). The work was published in the leading rheumatology journal, Arthritis and Rheumatology (doi.org/10.1002/art.41489). The Phase 2 study demonstrated a
Read MoreNorthSea Therapeutics doses first patient in Phase 1 trial of SEFA-1024 in dyslipidemia and further expands its clinical pipeline
NST becomes a multi-asset clinical development company, beyond NASH Pre-clinical studies have demonstrated broad and marked beneficial effects of SEFA-1024 on non-HDL cholesterol, triglycerides, and HDL cholesterol and glycemic control A third clinical development program, SEFA 6179, for treating Intestinal Failure- Associated Liver Disease (IFALD) will start Phase 1 studies
Read More
Oppilan Pharma Announces Positive Phase 1 Data for its Ulcerative Colitis Drug OPL-002 at Digestive Disease Week 2020 Virtual Scientific Program
Potential best-in-class profile for an oral sphingosine-1-phosphate receptor modulator – Dose-dependent reduction in circulating lymphocytes –– Rapid lymphocyte recovery after cessation of dosing –– Phase 2 study in ulcerative colitis patients in 4Q 2020 – ENCINITAS, California and Cambridge, United Kingdom, June 23, 2020 – Oppilan Pharma, Ltd., a clinical-stage
Read More
Zoll TherOx Receives CE Mark Approval for Supersaturated Oxygen Therapy
View Full Press Release >>
Read MoreFDA Approves Next-Generation ZOLL® TherOx System for Widowmaker Heart Attack Patients First
View Full Press Release >>
Read More